Lisdexamfetamine (Vyvanse) is a DEA Schedule II CNS stimulant prodrug approved for ADHD in children aged 6 and older and adults, and for moderate-to-severe binge eating disorder. After oral ingestion, red blood cell enzymes convert it to active d-amphetamine, which increases dopamine and norepinephrine in the brain to improve attention and impulse control. Common side effects include decreased appetite, insomnia, and elevated heart rate and blood pressure. The prodrug design creates a smoother 10–14 hour duration and reduces (but does not eliminate) abuse potential compared to immediate-release amphetamines.
Lisdexamfetamine
Uses & FDA Indications
Lisdexamfetamine (Vyvanse) is an FDA-approved CNS stimulant with two distinct approved indications: attention-deficit/hyperactivity disorder (ADHD) and moderate-to-severe binge eating disorder (BED) in adults. It is the first and only FDA-approved pharmacotherapy for binge eating disorder.
For ADHD, lisdexamfetamine is approved for use in adults and children aged 6 years and older. It is indicated for all three presentations of ADHD: predominantly inattentive, predominantly hyperactive-impulsive, and combined presentation. Clinical trials demonstrate improvements in sustained attention, impulsivity, and executive function.
For binge eating disorder in adults, lisdexamfetamine reduces the frequency of binge eating episodes. The mechanism by which it helps BED — beyond general appetite suppression — is not fully understood but likely involves dopaminergic and noradrenergic effects on impulsive behavior and reward pathways. Lisdexamfetamine is not approved for weight loss, and its use for obesity or routine weight management is not appropriate.
How It Works
Lisdexamfetamine is a therapeutically inactive prodrug. The capsule or chewable tablet contains lisdexamfetamine — a molecule consisting of d-amphetamine covalently bonded to the amino acid L-lysine. After oral ingestion and absorption, red blood cell enzymes (primarily peptidases) cleave the lysine moiety, releasing active d-amphetamine into systemic circulation.
The active d-amphetamine then works through two complementary mechanisms: it reverses the dopamine transporter (DAT) and norepinephrine transporter (NET), causing active release of dopamine and norepinephrine from presynaptic terminals; and it inhibits monoamine oxidase (MAO), slowing neurotransmitter breakdown. The result is substantially elevated dopaminergic and noradrenergic tone in the prefrontal cortex and striatum — regions critical for attention, working memory, impulse control, and executive function.
The prodrug design of lisdexamfetamine is not just a delivery gimmick — it has meaningful pharmacological consequences. Because conversion to d-amphetamine can only occur through enzymatic hydrolysis in red blood cells (not in the gut or liver), the rate of active drug release is rate-limited by that enzymatic step. This produces a smoother, more gradual plasma amphetamine curve with a lower peak-to-trough ratio compared to Adderall XR, and roughly 14 hours of therapeutic coverage from a single morning dose.
FDA BLACK BOX WARNING — ABUSE AND DEPENDENCE: Lisdexamfetamine has high potential for abuse and dependence. Amphetamines have been extensively misused. Administration for prolonged periods may lead to drug dependence. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events. Prescribe and dispense sparingly. Assess patients' risk for abuse before prescribing. Monitor for signs of abuse and dependence while on therapy.
Side Effects
Common
- Decreased appetite — the most common side effect; often significant, particularly in children. Can impair nutritional intake if not managed. Evening snacks and calorie-dense foods at mealtimes can help.
- Insomnia — stimulant-related difficulty initiating sleep; morning dosing and good sleep hygiene are essential. Taking lisdexamfetamine later in the day significantly worsens insomnia.
- Elevated heart rate and blood pressure — modest but consistent increases across clinical trials; monitor in patients with cardiovascular risk factors
- Irritability — particularly during dose wear-off in the afternoon/evening ("rebound"); more common in children
- Dry mouth — related to adrenergic stimulation; staying hydrated helps
- Weight loss — consequence of appetite suppression; growth monitoring is essential in children on long-term therapy
- Headache, dizziness, nausea — especially early in treatment
Serious
- Cardiovascular events — sudden death in patients with structural cardiac abnormalities or other serious cardiac conditions; serious cardiovascular events reported in adults. A thorough cardiac history is mandatory before prescribing.
- Psychiatric effects — new or worsened psychosis, mania, or aggression, particularly at higher doses or in predisposed individuals. Stimulants can unmask underlying bipolar disorder or psychotic conditions.
- Growth suppression — long-term stimulant use in children is associated with modest reductions in height and weight velocity. Monitor growth and consider drug holidays if significant suppression occurs.
- Serotonin syndrome — rare but possible, particularly in combination with serotonergic agents
- Raynaud's phenomenon — peripheral vasoconstriction; fingers or toes may turn white or blue in cold temperatures
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) | Concurrent or recent use of MAOIs with amphetamines can cause hypertensive crisis — potentially fatal rapid elevation of blood pressure. MAOIs block amphetamine metabolism and amplify catecholamine release dramatically. A 14-day washout of MAOIs before starting lisdexamfetamine is mandatory. | CONTRAINDICATED — absolute |
| Serotonergic Drugs (SSRIs, SNRIs, triptans, tramadol) | Amphetamines have serotonergic activity. Combination with other serotonergic agents increases serotonin syndrome risk, though this is less pronounced than with MAOIs. | Moderate — monitor for serotonin syndrome signs; use with caution |
| Antacids / Urinary Alkalinizers (sodium bicarbonate, high-dose vitamin C) | Urinary pH affects renal elimination of amphetamine. Alkalinizing agents increase reabsorption (prolong effect/toxicity). Acidifying agents increase elimination (reduce efficacy). Antacids can alter absorption as well. | Moderate — avoid concurrent use; separate timing if antacids are necessary |
| Antihypertensive Agents | Amphetamines increase blood pressure and heart rate, directly opposing the effects of antihypertensive medications. Blood pressure control may deteriorate in patients on both therapies. | Moderate — monitor blood pressure closely; may need antihypertensive dose adjustment |
| Lithium | Lithium may inhibit amphetamine-induced stimulant effects. May be used therapeutically in some contexts, but the pharmacodynamic interaction should be recognized. | Minor — monitor clinical response |
Warnings & Contraindications
Contraindications
- Concomitant use with MAO inhibitors or within 14 days of MAOI discontinuation
- Known hypersensitivity to amphetamine products
- Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension
- Hyperthyroidism
- History of drug abuse (relative; requires careful risk-benefit assessment)
Cardiovascular Screening
Before initiating lisdexamfetamine, all patients should have a thorough assessment of cardiovascular health, including personal and family history of sudden cardiac death, ventricular arrhythmia, or structural cardiac abnormality. Patients with known structural cardiac disease should generally not receive stimulants. Baseline and periodic blood pressure and heart rate monitoring is recommended for all patients during treatment.
Psychiatric History
Screen patients for personal or family history of bipolar disorder, psychosis, or mania before initiating stimulant therapy. Lisdexamfetamine can unmask latent psychiatric conditions. If psychotic or manic symptoms emerge during treatment, discontinue lisdexamfetamine and reassess the diagnosis.
Check for interactions between lisdexamfetamine and your other medications.
Check Drug Interactions →Frequently Asked Questions
Is Vyvanse stronger than Adderall?
Vyvanse (lisdexamfetamine) and Adderall (mixed amphetamine salts) are not directly comparable in terms of "strength" because they work somewhat differently. Lisdexamfetamine is a prodrug that must be enzymatically converted to d-amphetamine in the body, which produces a smoother, more gradual onset and a longer duration of action (~14 hours vs. 4–6 hours for immediate-release Adderall or ~8–12 hours for Adderall XR). Both ultimately deliver amphetamine to the brain; Vyvanse's gentler pharmacokinetic profile is the key clinical difference, not a difference in potency per se.
How long does Vyvanse last?
Lisdexamfetamine (Vyvanse) typically provides approximately 10–14 hours of therapeutic coverage after a single morning dose — significantly longer than immediate-release amphetamines. The prodrug mechanism accounts for this duration: the slow enzymatic conversion of lisdexamfetamine to active d-amphetamine in red blood cells creates a sustained, relatively consistent release of active drug, avoiding the sharp peaks associated with immediate-release stimulants. Individual response varies; some patients find effects waning earlier in the afternoon.
Can Vyvanse be abused?
Lisdexamfetamine carries a DEA Schedule II designation, reflecting recognized abuse potential. However, the prodrug design specifically reduces (but does not eliminate) abuse potential compared to immediate-release amphetamines. Because lisdexamfetamine is pharmacologically inert until enzymatically converted to d-amphetamine by red blood cell enzymes, crushing or snorting the capsule does not produce a faster or more intense effect — which reduces the appeal of insufflation compared to other stimulants. That said, oral abuse for performance enhancement or recreational use is still possible and reported.